Biotech Acquisition Accounts Payable

Biotech Acquisition posts a accounts payable of $0 as of September 2022. That compares with $360K in the prior-year period — down 100.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Biotech Acquisition's accounts payable was $360K. The latest reading is $0 — a 100.0% year-over-year decrease (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of Biotech Acquisition's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BIOT's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Biotech Acquisition's other metric pages and overview cover the third.